329 related articles for article (PubMed ID: 7954244)
1. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Corn BW; Yousem DM; Scott CB; Rotman M; Asbell SO; Nelson DF; Martin L; Curran WJ
Cancer; 1994 Nov; 74(10):2828-35. PubMed ID: 7954244
[TBL] [Abstract][Full Text] [Related]
2. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
3. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
4. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
Curran WJ; Scott CB; Nelson JS; Weinstein AS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG; Powlis WD
Cancer; 1992 Dec; 70(12):2909-17. PubMed ID: 1451073
[TBL] [Abstract][Full Text] [Related]
7. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
[TBL] [Abstract][Full Text] [Related]
8. Late radiation toxicity after whole brain radiotherapy: the influence of antiepileptic drugs.
Nieder C; Leicht A; Motaref B; Nestle U; Niewald M; Schnabel K
Am J Clin Oncol; 1999 Dec; 22(6):573-9. PubMed ID: 10597741
[TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
[TBL] [Abstract][Full Text] [Related]
10. 3D conformal radiotherapy and cisplatin for recurrent malignant glioma.
VanderSpek L; Fisher B; Bauman G; Macdonald D
Can J Neurol Sci; 2008 Mar; 35(1):57-64. PubMed ID: 18380278
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study.
Shaw E; Arusell R; Scheithauer B; O'Fallon J; O'Neill B; Dinapoli R; Nelson D; Earle J; Jones C; Cascino T; Nichols D; Ivnik R; Hellman R; Curran W; Abrams R
J Clin Oncol; 2002 May; 20(9):2267-76. PubMed ID: 11980997
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.
Douw L; Klein M; Fagel SS; van den Heuvel J; Taphoorn MJ; Aaronson NK; Postma TJ; Vandertop WP; Mooij JJ; Boerman RH; Beute GN; Sluimer JD; Slotman BJ; Reijneveld JC; Heimans JJ
Lancet Neurol; 2009 Sep; 8(9):810-8. PubMed ID: 19665931
[TBL] [Abstract][Full Text] [Related]
14. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28.
Epstein BE; Scott CB; Sause WT; Rotman M; Sneed PK; Janjan NA; Davis LW; Selim H; Mohiuddin M; Wasserman TH
Cancer; 1993 Feb; 71(4):1362-7. PubMed ID: 8435812
[TBL] [Abstract][Full Text] [Related]
15. Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial.
Fitzek MM; Thornton AF; Harsh G; Rabinov JD; Munzenrider JE; Lev M; Ancukiewicz M; Bussiere M; Hedley-Whyte ET; Hochberg FH; Pardo FS
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):131-7. PubMed ID: 11516862
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?
Nieder C; Andratschke N; Wiedenmann N; Busch R; Grosu AL; Molls M
Strahlenther Onkol; 2004 Jul; 180(7):401-7. PubMed ID: 15241527
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas.
Allen J; Siffert J; Donahue B; Nirenberg A; Jakacki R; Robertson P; DaRosso R; Thoron L; Rosovsky M; Pinto R
Cancer; 1999 Sep; 86(6):1064-9. PubMed ID: 10491535
[TBL] [Abstract][Full Text] [Related]
18. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Dinapoli RP; Brown LD; Arusell RM; Earle JD; O'Fallon JR; Buckner JC; Scheithauer BW; Krook JE; Tschetter LK; Maier JA
J Clin Oncol; 1993 Jul; 11(7):1316-21. PubMed ID: 8315428
[TBL] [Abstract][Full Text] [Related]
19. Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy.
Johannesen TB; Lien HH; Hole KH; Lote K
Radiother Oncol; 2003 Nov; 69(2):169-76. PubMed ID: 14643954
[TBL] [Abstract][Full Text] [Related]
20. Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: Implications for conformal dose-escalation studies.
Tsien C; Gomez-Hassan D; Ten Haken RK; Tatro D; Junck L; Chenevert TL; Lawrence T
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):328-32. PubMed ID: 15890571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
